TAMIGA: A PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF CONTINUOUS BEVACIZUMAB THROUGH MULTIPLE LINES OF TREATMENT FOR GLIOBLASTOMA

Alba Brandes, Miquel Gil Gil, Frank Saran, Antoine F. Carpentier, Anna Nowak, Warren Mason, Francois Dubois, Gaetano Finocchiaro, George Fountzilas, Vittorina Zagonel, Dana M. Cernea, Olivier Chinot, Martina Makrutzki, Chiedzo Mpofu, Hans-Joerg Urban, Josef Pichler

Research output: Contribution to journalAbstract/Meeting Abstract

Original languageEnglish
Pages (from-to)17-18
Number of pages2
JournalNeuro-Oncology
Volume19
Publication statusPublished - Nov 2017
Externally publishedYes
Event22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology - San Francisco, United States
Duration: 16 Nov 201719 Nov 2017

Cite this

Brandes, A., Gil Gil, M., Saran, F., Carpentier, A. F., Nowak, A., Mason, W., Dubois, F., Finocchiaro, G., Fountzilas, G., Zagonel, V., Cernea, D. M., Chinot, O., Makrutzki, M., Mpofu, C., Urban, H-J., & Pichler, J. (2017). TAMIGA: A PHASE II STUDY EVALUATING THE EFFICACY AND SAFETY OF CONTINUOUS BEVACIZUMAB THROUGH MULTIPLE LINES OF TREATMENT FOR GLIOBLASTOMA. Neuro-Oncology, 19, 17-18.